Mechanisms linking RAS signals to disordered hematopoiesis and myeloid neoplasia


Principal Investigator: BENJAMIN BRAUN
Abstract: DESCRIPTION (provided by applicant): Chronic and juvenile myelomonocytic leukemias (CMML and JMML) are myeloid diseases characterized by excessive myeloid proliferation and reduced numbers of red cells and platelets. Thus, they have features of both myelodysplastic syndromes (MDS) and myeloproliferative neoplasms (MPN). These "MDS/MPN" disorders carry a very poor prognosis, with most patients dying within 2 years of diagnosis. Somatic NRAS and KRAS mutations are common in MDS/MPN, and mice that express an activated KrasD12 allele develop a similar disease. This is characterized by profound myelomonocytic proliferation, severe anemia, early death and complete penetrance. Pathogenic bone marrow progenitors in KrasD12 mice demonstrate: (1) biased differentiation that favors the granulocyte/macrophage (GM) lineage at the expense of early megakaryocyte- erythroid (MegE) progenitors, (2) cytokine independent growth and (3) cell-intrinsic hypersensitivity to serum and the cytokine GM-CSF in committed GM progenitors. Despite intensive study of Ras signaling, the basic mechanisms by which Ras activation causes excessive myeloid cell production and anemia in MDS/MPN are unknown. Inhibition of the Raf/MEK/ERK cascade downstream of Ras was recently found to extend the lifespan of KrasD12 mice and correct progenitor abnormalities in vivo. However, the cellular mechanisms controlled by MEK in primary cells remain unknown. The proposed research will investigate the effects of hyperactive Ras/MEK signaling in hematopoiesis with the following aims: (1) in the mouse model, define mechanisms by which Ras/MEK signaling increases myeloid cell production;and (2) in patient samples, test the role of MEK activity in the abnormal growth and differentiation of human MDS/MPN cells. MEK is hypothesized to stimulate increased cell division rates and/or survival in GM progenitors, as well as alter the balance of GM vs. MegE lineage commitment in immature populations such as hematopoietic stem cells. This will be addressed using time lapse cell culture methods to observe cell fate in real time, and novel single cell gene expression studies to assess lineage choice. Specific transcription factors and genes regulated by MEK will be targeted by shRNA knockdown to evaluate their functional importance in primary cells. Aim 2 will be addressed in blood and bone marrow samples from JMML and CMML patients. The platforms developed to observe murine cells will be adapted to study sorted human progenitor cells. Quantitative measurements of sensitivity to MEK inhibition in vitro will be correlated to prognostic indices from diagnostic dat. Together, these studies will reveal cellular and molecular mechanisms of aberrant hematopoiesis in MDS/MPN driven by hyperactive Ras. They will also establish systems for translating discoveries in model systems to benefit patients by improving our ability to use in vitro studies to learn how specific agents affect cell fates. Biochemical mechanisms of disease that are conserved in murine and human systems will serve as high value targets for development of novel therapies for MDS/MPN.
Funding Period: 2013-07-02 - 2018-05-31
more information: NIH RePORT

Detail Information

Research Grants31

  1. B-cell Biology of Mucosal Immune Protection from SIV Challenge
    Eric Hunter; Fiscal Year: 2013
  2. Epidemiology of Breast Cancer Subtypes in African American Women: a Consortium
    Julie R Palmer; Fiscal Year: 2013
    ..By pooling our data, specimens, and importantly, expertise to investigate these synergist hypotheses, we will elucidate much of the etiology of aggressive, early onset breast cancers in AA women. ..
  3. M D Anderson Cancer Center Prosate SPORE
    Christopher J Logothetis; Fiscal Year: 2013
    ..We are optimistic that our research efforts will contribute to reductions in the incidence of, and morbidity and mortality from, this devastating disease by translating basic research into clinical practice. ..
  4. Magnetic Resonance Imaging-Guided Cancer Interventions
    Kim Butts Pauly; Fiscal Year: 2013
    ..abstract_text> ..
  5. University of Maryland Greenebaum Cancer Center Support Grant
    Kevin J Cullen; Fiscal Year: 2013
    ..Reflecting our remarkable and continued growth, UMGCC seeks to renew its CCSG to enhance and expand its efforts in high-quality and clinically relevant cancer research. ..
  6. Targeted Therapies in Melanoma
    MEENHARD FOLKENS HERLYN; Fiscal Year: 2013
    ..To account for the increased needs for compound synthesis and modification, we have added a Medicinal Chemistry Core (D) in this renewal application. ..
    Stuart H Orkin; Fiscal Year: 2013
    ..abstract_text> ..
    John C Crabbe; Fiscal Year: 2013
    ..An Education and Outreach component trains pre- and post-doctoral students in alcohol research, disseminates research findings to the public, and engages in a range of activities with elementary-to-high school students. ..
  9. Mechanisms of Impaired Erythropoiesis in Post Burn Anemia of Critical Illness
    ..Results gleaned from the experimental model combined with clinical data will provide the mechanistic insight into post burn anemia, which will pave the way for potential therapeutic interventions to treat anemia of critical illness. ..
  10. Role of the zinc finger transcription factor ZBP89 in blood &vascular developmen
    M Amin Arnaout; Fiscal Year: 2013
    ..We have discovered a transcription factor that lies at the cross road of blood and blood vessel development. We are proposing a series of studies to pinpoint the role of this factor, and define the developmental networks it coordinates. ..
    Michal Laniado Schwartzman; Fiscal Year: 2013
    ..ular tone, in the pathophysiology of hypertension and cardiovascular disease. ..
  12. Arterial Dysfunction: Basic and Clinical Mechanisms
    Thomas Michel; Fiscal Year: 2013
    ..Gladyshev. P. Libby directs the Redox Biomarkers Core;metabolic characterizations of mouse models studied in this Program will take place at the Yale Mouse Metabolic Phenotyping Center, led by G. Shulman. ..
  13. Molecular Pathways to Thynmic Lymphoma and Leukemia
    A Thomas Look; Fiscal Year: 2013
    ..Such interactions are expected to accelerate the pace at which important discoveries are generated in these projects and in the program as a whole. ..
  14. HSC Diversity: Regulation by Clonal Selection vs Epigenetic Induction
    Irving L Weissman; Fiscal Year: 2013
  15. Hyaluronan Matrices in Vascular Pathologies
    Vincent C Hascall; Fiscal Year: 2013
    ..abstract_text> ..
  16. Biology and Therapy of High Risk Neuroblastoma
    ROBERT CHARLES SEEGER; Fiscal Year: 2013, which includes 15 pediatric oncology institutions across the US and in Canada. ..